Yohimbe Alkaloids – General Discussion

  • P. A. G. M. De Smet
Part of the Adverse Effects of Herbal Drugs book series (HERBAL DRUGS, volume 3)


Yohimbine and related indole alkaloids occur in a number of botanical species. Their presence in the rubiaceous genera of Corynanthe and Pausinystalia will be reviewed in separate contributions to this volume.


Panic Attack Clonic Convulsion Psychogenic Impotence Organic Impotence Plasma MHPG 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Poisson J (1964) Recherches récentes sur les alcaloïdes du Pseudocinchona et du Yohimbe. Ann Chim (Paris) 9:99–121Google Scholar
  2. 2.
    Manske RHF (1965) Alkaloids of Pseudocinchona and Yohimbe. In: Manske RHF, red. The Alkaloids – Chemistry and Physiology. Volume 8: The indole alkaloids. New York: Academic Press, pp.693–723CrossRefGoogle Scholar
  3. 3.
    Hoppe HA (1975) Drogenkunde. Band 1. Angiospermen. 8. Auflage. Berlin: Walter de GruyterGoogle Scholar
  4. 4.
    Raymond-Hamet, Goutarel R (1965) L’Alchornea floribunda Mueller Arg. doit-il à la yohimbine ses effets excitants chez l’homme? C R Acad Sc Paris 261:3223–3224Google Scholar
  5. 5.
    Khuong-Huu F, Leforestier J-P, Maillard G, Goutarel R (1970) L’alchornéine, alcaloïde dérivé de la tétrahydro-imidazo-[1.2a] pyrimidine, isolé de deux Euphorbiacées africaines, l’Alchornea floribunda Muell. Arg. et l’Alchornea hirtella Benth. C R Acad Sc Paris Série C pp.2070–2072Google Scholar
  6. 6.
    Khuong-Huu F, Le Forestier JP, Goutarel R (1972) Alchornéine, isoalchornéine et alchor- néinone, produits isolés de l’Alchornea floribunda Muell. Arg. Tetrahedron 28:5207–5220CrossRefGoogle Scholar
  7. 7.
    Kohli JD, Balwani JH, Ray C, De NN (1957) Pharmacological action of rauwolscine: Part 1-Adrenergic blocking activity. Arch Int Pharmacodyn 111: 108–121PubMedGoogle Scholar
  8. 8.
    Demichel P, Gomond P, Roquebert J (1981) Pre- and postsynaptic α-adrenoreceptor blocking activity of raubasine in the rat vas deferens. Br J Pharmacol 74:739–745PubMedGoogle Scholar
  9. 9.
    Hohnloser E (1967) Kreislaufanalytische Untersuchungen unter der Einwirkung des blockwolfia-Alkaloids Raubasin. Arzneim Forsch 17:967–969Google Scholar
  10. 10.
    Wade A, Reynolds JEF, red. (1977) Martindale The Extra Pharmacopoeia. 27th edn. London: The Pharmaceutical Press, p. 1806Google Scholar
  11. 11.
    Lambert GA, Lang WJ, Friedman E, Meller E, Gershon S (1978) Pharmacological and biochemical properties of isomeric yohimbine alkaloids. Eur J Pharmacol 49:39–48PubMedCrossRefGoogle Scholar
  12. 12.
    Guthrie SK, Hariharan M, Grunhaus LJ (1990) Yohimbine bioavailability in humans. Eur J Clin Pharmacol 39:409–411PubMedCrossRefGoogle Scholar
  13. 13.
    Weitzell R, Tanaka T, Starke K (1979) Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit. Naunyn-Schmiedeberg’s Arch Pharmacol 308:127–136CrossRefGoogle Scholar
  14. 14.
    Timmermans PBMWM, Kwa HY, Van Zwieten PA (1979) Possible subdivision of postsynaptic α-adrenoceptors mediating pressor responses in the pithed rat. Naunyn-Schmie-deberg’s Arch Pharmacol 310:189–193CrossRefGoogle Scholar
  15. 15.
    Tanaka T, Starke K (1980) Antagonist/agonist-preferring α-adrenoceptors or α12-adrenoceptors? Eur J Pharmacol 63: 191–194PubMedCrossRefGoogle Scholar
  16. 16.
    Timmermans PBMWM, Schoop AMC, Kwa HY, Van Zwieten PA (1981) Characterization of α-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur J Pharmacol 70:7–15PubMedCrossRefGoogle Scholar
  17. 17.
    Ito Y, Yano S, Watanabe K, Yamanaka E, Aimi N, Sakai S-I (1990) Structure-activity relationship of yohimbine and its related analogs in blocking alpha-1 and alpha-2 adrenoceptors: a comparative study of cardiovascular activities. Chem Pharm Bull 38:1702–1706PubMedGoogle Scholar
  18. 18.
    Angel I, Niddam R, Langer SZ (1990) Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia. J Pharmacol Exp Ther 254:877–882PubMedGoogle Scholar
  19. 19.
    Creveling CR, Daly JW, Parfitt RT, Witkop B (1968) The chemorelease of norepinephrine from mouse hearts. IV. Structure-activity relationships. Reserpines and yohimbines. J Med Chem 11:596–598PubMedCrossRefGoogle Scholar
  20. 20.
    Morales A, Surridge DHC, Marshall PG, Fenemore J (1982) Nonhormonal pharmacological treatment of organic impotence. J Urol 128:45–47PubMedGoogle Scholar
  21. 21.
    Morales A, Surridge DH, Marshall PG (1982) Yohimbine for treatment of impotence in diabetes. N Engl J Med 305:1221Google Scholar
  22. 22.
    Charney DS, Heninger GR, Sternberg DE (1982) Assessment of α2 adrenergic autoreceptor function in humans: effects of oral yohimbine. Life Sci 30:2033–2041PubMedCrossRefGoogle Scholar
  23. 23.
    Goldberg MR, Robertson D (1983) Yohimbine: a pharmacological probe for study of the α2-adrenoreceptor. Pharmacol Rev 35: 143–180PubMedGoogle Scholar
  24. 24.
    Linden CH, Vellman WP, Rumack B (1985) Yohimbine: a new street drug. Ann Emerg Med 14:1002–1004PubMedCrossRefGoogle Scholar
  25. 25.
    Anonymous (1986) Yohimbine: time for resurrection? Lancet 2:1194–1195Google Scholar
  26. 26.
    Nickerson M (1949) The pharmacology of adrenergic blockade. Pharmacol Rev 1:27–101Google Scholar
  27. 27.
    Lambert GA, Lang WJ (1977) Interaction between yohimbine alkaloids and amphetamine in mice. Psychopharmacology 51:209–212PubMedCrossRefGoogle Scholar
  28. 28.
    Watanabe K, Yano S, Horiuchi H, Yamanaka E, Aimi N, Sakai S (1987) Ca2+ channel-blocking effect of the yohimbine derivatives, 14β-benzoyloxyyohimbine and 14β-p- nitrobenzoyloxyyohimbine. J Pharm Pharmacol 39:439–443PubMedCrossRefGoogle Scholar
  29. 29.
    Anonymous (1993) USP DI. Volume I–Drug Information for the Health Care Professional. 13th edn. Rockville: United States Pharmacopeial Convention, Inc., pp.2807–2808Google Scholar
  30. 30.
    Charney DS, Heninger GR (1986) α2-Adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. Arch Gen Psychiatry 43:1037–1041PubMedGoogle Scholar
  31. 31.
    Morales A, Condra M, Owen J A, Surridge DH, Fenemore J, Harris C (1987) Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 137: 1168–1172PubMedGoogle Scholar
  32. 32.
    Reid K, Surridge DHC, Morales A, Condra M, Harris C, Owen J, Fenemore J (1987) Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 2:421–423PubMedCrossRefGoogle Scholar
  33. 33.
    Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha MG (1989) Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 141:1360–1363PubMedGoogle Scholar
  34. 34.
    Young FE (1989) Aphrodisiac drug products for over-the-counter human use. Final rule. Fed Reg 54:28780–28786Google Scholar
  35. 35.
    Thesen R, Schulz M, Braun R (1990) Ganz oder teilweise “negativ” bewertete Arzneistoffe. Pharm Ztg 135:1812–1814Google Scholar
  36. 36.
    Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS (1993) Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol 22:22–26PubMedCrossRefGoogle Scholar
  37. 37.
    Reynolds JEF, red. (1993) Martindale The Extra Pharmacopoeia. 30th edn. London: The Pharmaceutical Press, p. 1428Google Scholar
  38. 38.
    Robertson D, Goldberg MR, Tung C-S, Hollister AS, Robertson RM (1986) Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Invest 78:576–581PubMedCrossRefGoogle Scholar
  39. 39.
    Ahmad RAS, Watson RDS (1990) Treatment of postural hypotension. Drugs 39:74–85PubMedCrossRefGoogle Scholar
  40. 40.
    Chatelut E, Rispail Y, Berlan M, Montastruc JL (1989) Yohimbine increases human salivary secretion. Br J Clin Pharmacol 28:366–368PubMedGoogle Scholar
  41. 41.
    Bagheri H, Schmitt L, Berlan M, Montastruc JL (1992) Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants. Br J Clin Pharmacol 34:555–558PubMedGoogle Scholar
  42. 42.
    Anonymous (1993) Vidal 1993. Paris: Editions du Vidal, pp.354,474,726,1576–1577Google Scholar
  43. 43.
    Berlin I, Stalla-Bourdillon A, Thuillier Y, Turpin G, Puech AJ (1986) Absence d’efficacité de la yohimbine dans le traitement de l’obésité. J Pharmacol 17:343–347PubMedGoogle Scholar
  44. 44.
    Kucio C, Jonderko K, Piskorska D (1991) Does yohimbine act as a slimming drug? Isr J Med Sci 27:550–556PubMedGoogle Scholar
  45. 45.
    Berlan M, Le Verge R, Galitzky J, Le Corre P (1993) α2-Adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine. Br J Pharmacol 108:927–932PubMedGoogle Scholar
  46. 46.
    Hesse E, Langer J (1931) Zur Pharmakologie der Yohimbealkaloide. Med Klin 27:1536-1537Google Scholar
  47. 47.
    Kreitmar H (1928) Pharmakologischer Teil. Merck’s Jahresbericht 24:22–26Google Scholar
  48. 48.
    Kohli JD, De NN (1956) Pharmacological action of rauwolscine. Nature (London) 177:1182CrossRefGoogle Scholar
  49. 49.
    Tangri KK, Bhargava KP (1961) Central component of vasomotor activity of yohimbine and its stereo-isomer rauwolscine. Arch Int Pharmacodyn 130:266–279PubMedGoogle Scholar
  50. 50.
    Das NN, Dasgupta SR, Mukherjee KL, Werner G (1955) Haemodynamic effects of rauwolscine. J Indian Med Res 43:101–106Google Scholar
  51. 51.
    Rockhold RW, Gross F (1981) Yohimbine diastereoisomers: cardiovascular effects after central and peripheral application in the rat. Naunyn-Schmiedeberg’s Arch Pharmacol 315:227–231CrossRefGoogle Scholar
  52. 52.
    Papeschi R, Sourkes TL, Youdim MBH (1971) The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. Eur J Pharmacol 15:318–326PubMedCrossRefGoogle Scholar
  53. 53.
    Serle JB, Podos SM, Lustgarten JS, Teijelbaum C, Severin CH (1985) The effect of corynanthine on intraocular pressure in clinical trials. Ophthalmology 92:977–980PubMedGoogle Scholar
  54. 54.
    Paris R, Janot M-M, Goutarel R (1945) Sur quelques propriétés physiologiques et en particulier sur l’action sympathicolytique de la corynanthéidine. C R Soc Biol 139: 665–666Google Scholar
  55. 55.
    Marzo A, Ghirardi P, Alessio R, Villa A (1977) Absorption and excretion of 3H-raubasine in human subjects and dogs. Arzneim Forsch 27:2343–2344Google Scholar
  56. 56.
    Neuman J, De Engel AMF, Neuman MP (1986) Pilot study of the effect of raubasine on platelet biological activity. Arzneim Forsch 36:1394–1398Google Scholar
  57. 57.
    Weidinger P (1970) Ergebnisse der klinischen Prüfung von Raubasin. Med Welt 10:403-408PubMedGoogle Scholar
  58. 58.
    Glocke M, Grübl M, Klein K, Teufel W (1976) Wirkungsnachweis von Raubasin aus einer neuen Rezeptur von Lamuran® Dragees. Med Klin 71:1564–1568PubMedGoogle Scholar
  59. 59.
    Owen J A, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A (1987) The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 32:577–582PubMedCrossRefGoogle Scholar
  60. 60.
    Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B, Petterson A (1992) Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol 43:651–656PubMedCrossRefGoogle Scholar
  61. 61.
    Le Verge R, Le Corre P, Chevanne F, Döe De Maindreville M, Royer D, Levy J (1992) Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. J Chromatogr 574:283–292PubMedCrossRefGoogle Scholar
  62. 62.
    Raymond-Hamet, Rothlin E (1960) Toxicité et activité utéro-adrénalinolytique, d’une part de quelques stéréo-isomères de la yohimbine, d’autre part de la δ-yohimbine ou raubasine. Compt Rend Soc Biol (Paris) 154:2037–2039Google Scholar
  63. 63.
    Paris R, Janot M-M, Goutarel R (1945) Toxicité de la corynanthéidine, nonvel alcaloïde cristallisé des écorces de Pseudocinchona africana Aug.Chev. Compt Rend Soc Biol 139:663–664Google Scholar
  64. 64.
    Bourin M, Malinge M, Colombel M-C, Larousse C (1988) Influence of alpha stimulants and beta blockers on yohimbine toxicity. Progr Neuro-Psychopharmacol Biol Psychiat 12:569-574Google Scholar
  65. 65.
    Quinton RM (1963) The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol 21:51–66Google Scholar
  66. 66.
    Holmberg G, Gershon S (1961) Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia 2:93–106PubMedCrossRefGoogle Scholar
  67. 67.
    Anonymous (1993) Physicians’ Desk Reference. 47th edn. Montvale: Medical Economics Company Inc., pp.929,1217 and 1739Google Scholar
  68. 68.
    Margolis R, Sangree H, Prieto P, Stein L, Chinn S (1967) Clinical studies on the use of Afrodex in the treatment of impotence: statistical summary of 4000 cases. Curr Ther Res 9:213–219PubMedGoogle Scholar
  69. 69.
    Charney DS, Heninger GR, Redmond Jr. DE (1983) Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 33:19–29PubMedCrossRefGoogle Scholar
  70. 70.
    Henauer SA, Gillespie HK, Hollister LE (1983) Yohimbine and the model anxiety state. J Clin Psychiatry 45:512–515Google Scholar
  71. 71.
    Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubier Y, Puech AJ (1989) Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharmacol Ther 45:241–251PubMedCrossRefGoogle Scholar
  72. 72.
    Galitzky J, Rivière D, Tran MA, Montastruc JL, Berlan M (1990) Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol 39:447–451PubMedCrossRefGoogle Scholar
  73. 73.
    Berlin I, Crespo-Laumonnier B, Cournot A, Landault C, Aubin F, Legrand J-C, Puech AJ (1991) The α2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol Ther 49: 362–369PubMedCrossRefGoogle Scholar
  74. 74.
    Mattila M, Seppala T, Mattila MJ (1988) Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol 3:215–229PubMedCrossRefGoogle Scholar
  75. 75.
    Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D (1987) Oral yohimbine in human autonomic failure. Neurol 37:215–220Google Scholar
  76. 76.
    Anonymous (1990) Yohimbe. Lawrence Rev Nat Prod, March 1990Google Scholar
  77. 77.
    Friesen K, Palatnick W, Tenenbein M (1993) Benign course after massive ingestion of yohimbine. J Emerg Med 11:287–288PubMedCrossRefGoogle Scholar
  78. 78.
    Varkey S (1992) Overdose of yohimbine. Br Med J 304:548CrossRefGoogle Scholar
  79. 79.
    Patscheider H, Dirnhofer R (1973) Tödliche Vergiftung eines Kleinkindes durch Yohimbin. Beitr Gerichtl Med 30:336–344PubMedGoogle Scholar
  80. 80.
    Young FE, Heckler MM (1985) Aphrodisiac drug products for over-the-counter human use. Fed Reg 50:2168–2170Google Scholar
  81. 81.
    Giessauf W, Pogglitsch H (1970) über die Wirkung von Raubasin auf die Nierenfunktion. Wien Med Wschr 120:291–293Google Scholar
  82. 82.
    Poitrenaud J, Piette F, Malbezin M, Sebban C, Guez D (1990) Almitrine-raubasine and cognitive impairment in the elderly: results of a 6-month controlled multicenter study. Clin Neuropharmacol 13 (Suppl 3):S100-S108PubMedGoogle Scholar
  83. 83.
    Guez D (1990) Longterm effects and safety of almitrine-raubasine in age-associated cognitive decline. Clin Neuropharmacol 13 (Suppl 3):S109-S116PubMedGoogle Scholar
  84. 84.
    Sandler B, Aronson P (1993) Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 41:343–345PubMedCrossRefGoogle Scholar
  85. 85.
    De Smet PAGM, Smeets OSNM (1994) Potential risks of health food products containing yohimbe extracts. Br Med J 309:958Google Scholar
  86. 86.
    Gershon S, Lang WJ (1962) A psycho-pharmacological study of some indole alkaloids. Arch Int Pharmacodyn 135:31–56PubMedGoogle Scholar
  87. 87.
    Goldberg MR, Hollister AS, Robertson D (1983) Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans. Hypertension 5:772–778PubMedGoogle Scholar
  88. 88.
    Goldstein DS, Eisenhofer G, Garty M, Sax FL, Keiser HR, Kopin IJ (1989) Pharmacologic and tracer methods to study sympathetic function in primary hypertension. Clin Exp Theory Pract All (Suppl. 1): 173–189Google Scholar
  89. 89.
    Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751–763PubMedGoogle Scholar
  90. 90.
    De Jongh DK, Van Proosdij-Hartzema EG (1955) Investigations into experimental hypertension. IV. The acute effects of Rauwolfia alkaloids on the blood pressure of rats with experimental renal hypertension. Acta Physiol Pharmacol Need 4:175–186Google Scholar
  91. 91.
    Dunn RW, Corbett R (1992) Yohimbine-induced seizures involve NMD A and GABAergic transmission. Neuropharmacol 31:389–395CrossRefGoogle Scholar
  92. 92.
    Rosenblum LA, Coplan JD, Friedman S, Bassoff T (1991) Dose-response effects of oral yohimbine in unrestrained primates. Biol Psychiatry 29:647–657PubMedCrossRefGoogle Scholar
  93. 93.
    Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Neurobiological mechanisms of panic anxiety: biochemical and behavioral corellates of yohimbine-induced panic attacks. Am J Psychiatry 144:1030–1036PubMedGoogle Scholar
  94. 94.
    Price LH, Charney DS, Heninger GR (1984) Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 141:1267–1268PubMedGoogle Scholar
  95. 95.
    Fontaine Ch (1968) Influence de la raubasine a doses fortes sur la réadaptation de malades atteints d’affections vasculaires cérébrales. Sem Hop 44:806–809PubMedGoogle Scholar
  96. 96.
    Charney DS, Breier A, Jatlow PI, Heninger GR (1986) Behavioral, biochemical and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. Psycho-pharmacology 88:133–140Google Scholar
  97. 97.
    Price LH, Charney DS, Rubin AL, Heninger GR (1986) α2-Adrenergic receptor function in depression. The Cortisol response to yohimbine. Arch Gen Psychiatry 43:849–858PubMedGoogle Scholar
  98. 98.
    Gold MS, Donabedian RK, Redmond Jr. DE (1979) Further evidence for alpha-2 adrenergic receptor mediated inhibition of prolactin secretion: the effect of yohimbine. Psychoneuroen-docrinology 3:253–260CrossRefGoogle Scholar
  99. 99.
    Espinoza N, Westermann B (1967) Untersuchungen über den Einfluss von Raubasin auf den Kohlenhydratstoffwechsel von Diabetikern. Dtsch Med Wschr 92:1562–1564PubMedCrossRefGoogle Scholar
  100. 100.
    Landis E, Shore E (1989) Yohimbine-induced bronchospasm. Chest 96:1424PubMedCrossRefGoogle Scholar
  101. 101.
    Ortmann R, Mutter M, Delini-Stula A (1982) Effect of yohimbine and its diastereoisomers on clonidine-induced depression of exploration in the rat. Eur J Pharmacol 77:335–337PubMedCrossRefGoogle Scholar
  102. 102.
    Liljequist S, Berggren U, Engel J (1981) The effect of catecholamine receptor antagonists on ethanol-induced locomotor stimulation. J Neural Transm 50:57–67PubMedCrossRefGoogle Scholar
  103. 103.
    Sanghvi I, Urquiaga X, Gershon S (1971) Exploration of the anti-depressant potential of L-DOPA. Psychopharmacologia 20: 118–127PubMedCrossRefGoogle Scholar
  104. 104.
    Geyer HJ, Sanghvi I, Gershon S (1973) Exploration of the anti-depressant potential of lithium. Psychopharmacologia 28:107–113PubMedCrossRefGoogle Scholar
  105. 105.
    Lang WJ, Lambert GA, Rush ML (1975) The role of the central nervous system in the cardiovascular responses to yohimbine. Arch Int Pharmacodyn 217:57–67PubMedGoogle Scholar
  106. 106.
    Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL, Graves ME, Schäfer SG, Christen MO (1994) A novel mechanism of action for hypertension control: moxonidine as a selective 11-imidazoline agonist. Cardiovasc Drugs Ther 8:27–41PubMedCrossRefGoogle Scholar
  107. 107.
    Charney DS, Price LH, Heninger GR (1986) Desipramine-yohimbine combination treatment of refractory depression. Implications for the (3-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 43:1155–1161PubMedGoogle Scholar
  108. 108.
    Bagheri H, Picault P, Schmitt L, Houin G, Berlan M, Montastruc JL (1994) Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants. Br J Clin Pharmacol 37:93–96PubMedGoogle Scholar
  109. 109.
    Ingram CG (1962) Some pharmacologic actions of yohimbine and chlorpromazine in man. Clin Pharmacol Ther 3:345–352Google Scholar
  110. 110.
    Itil T, Fink M (1968) EEG and behavioral aspects of the interaction of anticholinergic hallucinogens with centrally active compounds. Progr Brain Res 28:149–168CrossRefGoogle Scholar
  111. 111.
    Pichler L, Kobinger W (1985) Possible function of α1-adrenoceptors in the CNS in anaesthetized and conscious animals. Eur J Pharmacol 107:305–311PubMedCrossRefGoogle Scholar
  112. 112.
    Prud’Homme MJ (1988) Effect of α-adrenergic blocking agents on uterine activity in the ewe at the end of gestation. Acta Physiol Hungar 71:485–489Google Scholar
  113. 113.
    Lechner W, Daxenbichler G, Marth Ch (1987) Wehenhemmung mit α-Adrenorezepto-renblockern. Z Geburtshilfe Perinatol 191:102–104PubMedGoogle Scholar
  114. 114.
    Bovet-Nitti F, Bovet D (1959) Action of some sympathicolytic agents on pregnancy in the rat. Proc Soc Exp Biol Med 100: 555–557PubMedGoogle Scholar
  115. 115.
    Von Poser G, Andrade HHR, Da Silva KVCL, Henriques AT, Henriques JAP (1990) Genotoxic, mutagenic and recombinogenic effects of rauwolfia alkaloids. Mutat Res 232:37–43Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • P. A. G. M. De Smet

There are no affiliations available

Personalised recommendations